Microsens Biotechnologies, London Bioscience Innovation Centre, 2 Royal College Street London, NW1 0NH
Tel. +44 (0)20 76912147, Fax. +44 (0)20 76912036, Email info@microsens.co.uk
New for 2011
The Seprion ligand is used by the Health Protection Agency, UK in their tonsil screening programme and worldwide for food safety in the screening of millions of cattle for BSE
An introduction to the Seprion ligand range
The Seprion ligand range of products detects aggregated proteins. We have products for monitoring the aggregation state of manufactured therapeutic proteins such as antibodies and for detection of aggregated proteins associated with disease including Parkinson’s, Alzheimer’s, Huntington’s and the Transmissible Spongiform Encephalopathies such as BSE, scrapie, vCJD and CWD.
For diagnosis, detection and research studies it is very difficult to differentiate
the abnormal aggregated form of the proteins from the normal unaggregated form. To
address this problem, Microsens has developed polymeric ligands (the ‘Seprion’ range)
which only bind to the abnormal or altered aggregated form of the protein. The Seprion
ligands have been shown to bind aggregated antibodies, abnormal prion, β-
The Seprion ligands have been used extensively in commercial BSE screening and in research applications such as the screening of tonsils for vCJD or in mouse models of various Protein Aggregation Diseases.
The Seprion ligands are supplied coated onto magnetic beads or onto 96-
For more information. Please select a link on the left.
- EIA for aggregated amyloid
- The flexibility of PAD beads to purify any protein aggregate
- Detection of aggregates in production of therapeutic proteins